Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

A Multicenter, Single-blind, Within-subject, Placebo-controlled Proof of Concept Study to Assess the Effect of Single Oral Doses of BGG492 on the Photoparoxysmal EEG Response in Patients With Photosensitive Epilepsy

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00784212

Enrollment

Registered

2008-11-03

Start date

2008-10-31

Completion date

2010-09-30

Last updated

2016-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Photosensitive Epilepsy

Keywords

Photosensitive Epilepsy, photic stimulation, electroencephalogram

Brief summary

This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Interventions

DRUGBGG492

DRUGPlacebo

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* diagnosis of photosensitive epilepsy

Exclusion criteria

\- inconsistent photoparoxysmal response when stimulated by photic stimulation Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Outcome Measure: Photoparoxysmal response (PPR) and standardized photoparoxysmal response (SPR) determined by EEG on all treatment days.	Days 1, 2 and 3

Secondary

Measure	Time frame
Outcome Measure: Safety and tolerability of BGG492 in patients with photosensitive epilepsy	From Day 1 until Day 33 after treatment start.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026